{"cluster": 65, "subcluster": 3, "abstract_summ": "Having a potent antibody that can recognize the viral spike protein with high affinity would be enabling for both the design of sensitive SARS-CoV-2 detection devices and for their deployment as therapeutic antibodies.An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, yet there is no consensus as to which assay should be used for such measurements.The two assays will help define correlates of protection for antibody-based countermeasures including therapeutic antibodies, immune \u03b3-globulin or plasma preparations, and vaccines against SARS-CoV-2.An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, which engages with host ACE2 receptor for entry.These studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3\u201353/VH3\u201366 and similarity to a SARS-CoV VH3\u201330 antibody, providing criteria for evaluating vaccine-elicited antibodies.", "title_summ": "De novo design of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike proteinStructures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodiesNeutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.", "title_abstract_phrases": "Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodiesNeutralizing antibody responses to coronaviruses focus on the trimeric spike, with most against the receptor-binding domain (RBD).Having a potent antibody that can recognize the viral spike protein with high affinity would be enabling for both the design of sensitive SARS-CoV-2 detection devices and for their deployment as therapeutic antibodies.These studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3\u201353/VH3\u201366 and similarity to a SARS-CoV VH3\u201330 antibody, providing criteria for evaluating vaccine-elicited antibodies.De novo design of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike proteinThe emergence of SARS-CoV-2 is responsible for the pandemic of respiratory disease known as COVID-19, which emerged in the city of Wuhan, Hubei province, China in late 2019.The two assays will help define correlates of protection for antibody-based countermeasures including therapeutic antibodies, immune \u03b3-globulin or plasma preparations, and vaccines against SARS-CoV-2."}